ImmunityBio, Inc.
NASDAQ:IBRXBiotechnology
+$0.18 today
- Market cap
- $7.13B
- Beta
- 0.10
- P/E (TTM)
- -8.6
- EPS (TTM)
- -$0.83
Volume 15.77M
Average 16.40M
IBRX Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
ImmunityBio, Inc.NASDAQ: IBRX
Depreciation & Amortization · Q3 FY2026 · quarter ended Sep 2026
Depreciation & amortization dips below year-ago levels
Q3 FY2026 depreciation & amortization of $3.89M fell 1.6% year over year, behind the +4.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 11.8% from the prior quarter. Over 3 fiscal years it compounded at -5.3% a year.
Context
- Depreciation & amortization amounted to 13.7% of revenue in FY2025, down 105.3 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -1.6% toward the trailing-twelve-month pace of +4.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 15.53M USD
- Year-over-year change
- -11.6%
- 4-year CAGR
- +2.2%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 15.53M | -11.6% |
| FY2024 | 2024-12-31 | 17.55M | -5.2% |
| FY2023 | 2023-12-31 | 18.51M | +1.4% |
| FY2022 | 2022-12-31 | 18.26M | +28.2% |
| FY2021 | 2021-12-31 | 14.24M | — |
Depreciation & Amortization vs competitors
How IBRX compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +4.6% is the 5th highest of 11, against a peer median of -3.7%.
- Depreciation & amortization amounts to 9.1% of revenue for IBRX, versus a peer median of 9.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | €676.85M EUR | +122.9% | +43.9% | 25.6% | |
| LTM Sep 2026 | $257M USD | +23.6% | -14.8% | 10.2% | |
| LTM Sep 2026 | $50.27M USD | +111.9% | +16.3% | 3.7% | |
| LTM Sep 2026 | $33.47M USD | -27.6% | +30.8% | 8.8% | |
| LTM Mar 2026 | $18.23M USD | +41.3% | +46.1% | 27.8% | |
| LTM Sep 2026 | $16.54M USD | +4.6% | -5.3% | 9.1% | |
| LTM Mar 2026 | $12.13M USD | -8.0% | -4.7% | — | |
| LTM Mar 2026 | €12.05M EUR | -2.4% | +19.6% | 32.3% | |
| LTM Mar 2026 | $8.74M USD | -5.0% | +20.5% | — | |
| LTM Mar 2026 | $3.36M USD | -17.0% | -23.1% | 0.9% | |
| LTM Mar 2026 | $175K USD | -96.8% | -25.1% | 0.8% | |
| Peer median (excluding IBRX) | — | -3.7% | +17.9% | 9.5% | |
Competitors are the stored peer set for IBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (346.79M) | (416.57M) | (583.85M) | (413.65M) | (351.47M) |
| Depreciation & Amortization | 14.24M | 18.26M | 18.51M | 17.55M | 15.53M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 57.18M | 40.18M | 49.16M | 34.43M | 36.81M |
| Change in Working Capital | (15.4M) | (16M) | 3.83M | (19.42M) | (54.33M) |
| Accounts Receivables | 0 | 0 | 0 | (2.36M) | (40.21M) |
| Inventory | 0 | 0 | 0 | (8.27M) | (6.33M) |
| Accounts Payables | 0 | 0 | (6.48M) | (3.17M) | (190K) |
| Other Working Capital | (15.4M) | (16M) | 10.3M | (5.62M) | (7.6M) |
| Other Non-Cash Items | 16.35M | 36.62M | 145.44M | (10.16M) | 48.53M |
| Operating Cash Flow | (274.42M) | (337.51M) | (366.76M) | (391.24M) | (304.94M) |
| Capital Expenditures | (33.56M) | (78.16M) | (30.58M) | (6.89M) | (3.85M) |
| Acquisitions (Net) | 0 | 0 | 0 | (1M) | 0 |
| Purchases of Investments | 0 | 0 | (10.36M) | (140.22M) | (241.37M) |
| Sales of Investments | 0 | 0 | 10.47M | 136.61M | 95.82M |
| Other Investing Activities | (51.32M) | 105.46M | 0 | (747K) | 0 |
| Investing Cash Flow | (84.89M) | 27.3M | (30.47M) | (12.25M) | (149.8M) |
| Debt Repayment | 338.5M | 174.07M | 451.39M | 96.89M | 1.72M |
| Common Stock Issued | 0 | 0 | 110.4M | 111.36M | 400.78M |
| Common Stock Repurchased | (4.06M) | (616K) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 171.01M | 60.16M | (3.44M) | 73.38M | (2.27M) |
| Financing Cash Flow | 505.44M | 233.61M | 558.34M | 281.63M | 400.24M |
| Effect of Forex Changes | 48K | 284K | (292K) | (23K) | 15K |
| Net Change in Cash | 146.19M | (76.32M) | 160.82M | (121.88M) | (54.48M) |
| Free Cash Flow | (307.98M) | (415.67M) | (397.34M) | (398.12M) | (308.78M) |
ImmunityBio, Inc.
NASDAQ:IBRX
Intrinsic Alpha fair value
Locked
Current Price
$6.70
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.